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ABSTRACT 
Background: The transmission of malaria has increased in 
recent years in many countries where it was once eradicated 
or under control, and malaria remains a major cause of mor- 
bidity and mortality throughout the developing world. Imported 
cases of malaria have been increasing in New York City and 
throughout the United States during the past decade. The New 
York City Department of Health has modified its malaria sur- 
veillance program in order to improve the assessment of diag- 
nosis and treatment of malaria in New York City residents and 
to provide appropriate advice to health professionals who treat 
these patients. 
Objectives: To describe the epidemiologic and clinical charac- 
teristics of laboratory-confirmed cases of malaria diagnosed in 
New York City residents from January 1, 1991, through Decem- 
ber 31, 1996. 
Methods: The retrospective study of case reports was carried 
out by the Malaria Surveillance Program of the Bureau of Com- 
municable Diseases, New York City Depaltment of Health, New 
York City, NY. It included the laboratory diagnosis of malaria and 
the species involved, and included also descriptive epidemio- 
logic information of patients with malaria (age, sex, race/eth- 
nicity, date and place of onset of illness, travel history, 
immigration status, previous history of malaria, history of blood 
transfusion, drugs used for treatment or prophylaxis), as well 
as a record of clinical complications of the infection (thrombo- 
cytopenia, hemolysis, anemia, cerebral malaria, renal failure, 
respiratory distress syndrome, fatal outcome). 
Results: Malaria was diagnosed in 988 residents of New York 
City during the 5-year period from January 1, 1991, through 
December 31, 1995. The largest number of cases, 254 (26%), 
occurred in 1996, with the majority of these cases (76%) 
observed between the months of May and October. Sixty-four 
percent (627) of these cases were males. The age range of 
cases was from newborn (first day of life) to 83 years (median, 
31 years). Of the 962 cases of whom the racial/ethnic identity 
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was known, 580 (59%) were black/non-Hispanic and 255 (26%) 
were Asian/Pacific Islander. Travel outside of the United States 
was reported by 958 patients, the majority to Africa (569/958, 
59%). Only 139 patients (14%) claimed the use of malaria pro- 
phylaxis during travel. Plasmodium falciparum was identified in 
505 (51%) and F! vivax in 356 (36%) of the cases. Clinical com- 
plications included hemolysis with severe anemia, thrombocy- 
topenia, cerebral malaria, renal failure, and respiratory distress 
syndrome. All four fatal cases involved infections with F! falci- 
pat-urn, either alone or in combination with another plasmodia 
species. 
Conclusions: Imported cases of malaria occur frequently in 
New York City and may be associated with serious complica- 
tions. Health care providers should consider this diagnosis in 
patients who have recently travelled or arrived from abroad, 
presenting with headache, fever, and other constitutional symp- 
toms. There are many missed opportunities for the use of 
malaria prophylaxis, and physicians should familiarize them- 
selves with current recommendations for malaria prophylaxis for 
travel to areas of the world where people are at risk for the 
transmission of malaria. 
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An estimated 300 to 500 million people worldwide are 
infected with malaria,’ and 2.7 million deaths per year 
occur among infected individuak2 It is a particularly 
important cause of morbidity3 and mortality throughout 
the developing world, especially sub-Saharan Africa.* 
Once a significant health problem in parts of Europe, the 
United States, and other industrialized countries, malaria 
is now primarily an imported disease, acquired by trav- 
ellers, immigrants, and military personnel5 arriving from 
regions of the world where malaria remains endemic. 
Recent years have seen an increase in the transmission 
of malaria in many countries where it had been once 
eradicated or well controlled. This has been due in large 
part to population growth and movement and the failure 
of previously successful mosquito control programs, allow- 
ing malaria to maintain its place as a major contributor 
to the global burden of disease.6 Malaria may pose a diag- 
nostic challenge to the physician who does not have 
experience with the disease. These cases also pose a ther- 
apeutic challenge because Plasmodium falciparum and 
Plasmodium vivax have both developed resistance to 
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chloroquine, and multiple-drug resistant l? falciparum 
has appeared in Southeast Asia.7-9 Due to an increase in 
cases of imported malaria in New York City, the Depart- 
ment of Health (NYCDOH) has modified its malaria sur- 
veillance program in order to improve the assessment of 
diagnosis and treatment of malaria in New York City res- 
idents and to provide appropriate advice to health pro- 
fessionals who treat these infected patients. 
METHODS 
Malaria is reportable to the NYCDOH once the suspected 
illness is confirmed by laboratory diagnosis. A clonfirmed 
case is considered to be one in which microscopically- 
confirmed malaria parasites are demonstrated on a 
peripheral blood smear. lo A laboratory-confirmed case is 
reported to the NYCDOH on a standard reporting form 
or by telephone. A detailed case-report form containing 
clinical, epidemiologic, and laboratory information is com- 
pleted by NYCDOH staff through telephone interviews 
and medical chart reviews. Information obtained includes: 
age, sex, race/ethnic&y, date and place of onset ‘of illness, 
name and address of treating physician, laboratory results, 
species, travel history, previous history of malar:ia, history 
of blood transfusion, clinical complications (hemolysis, 
cerebral malaria, renal failure, and other), drugs used for 
treatment, and use of malaria prophylaxis (drug used if 
indicated). Detailed clinical information beyond the above 
parameters was not collected in this surveillance pro- 
gram. Peripheral blood smears may be forwarded to the 
New York City Bureau of Laboratories when species iden- 
tification is uncertain. The information from the stan- 
dardized case report form is entered into the NYCDOH 
database for further analysis. 
The data were analyzed using SPSS for Windows, ver- 
sion 6.1. Cases of malaria diagnosed in nonresidents of 
New York City were excluded from analysis for this 
report. 
RESULTS 
Malaria was diagnosed in 988 residents of NewYork City 
during the 6-year period from January 1, 19911, through 
December 31, 1996 (Figure 1). The annual number of 
cases ranged from 120 cases in 1991 to 254 cases in 1996 
(mean, 165 cases per year). From 1991 to 1995 the annual 
number of cases remained below 150; holwever, an 
increase in reported cases and case rates occurred dur- 
ing the years 1995 and 1996 (range, 1.64 cases/lOO,OOO 
population in 1992 to 3.47/100,000 populatioa in 1996; 
mean rate, 2.25/100,000 population for the 6-year period). 
Six hundred and fifty-seven cases of malaria (67%) 
were diagnosed between the months of May and Octo- 
ber (Figure 2) which probably reflects the travel for sum- 
mer vacation. 
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Figure 1. Frequency of malaria by year of diagnosis in New York 
City, 1991-l 996. 
The majority of cases occurred in males (627; 64%) 
and 282 cases (36%) in females. The gender information 
was unavailable for 79 individuals. The age range for 
patients with malaria was from newborn (first day of life) 
to 83 years (median age, 31 years). The rate of malaria per 
100,000 people was greatest for males in all age groups 
and was highest for patients aged 1 to 4 years and 20 to 
44 years (Figure 3). 
Information on racial/ethnic identity was available 
for 962 (97%) of the patients diagnosed with malaria: 580 
(59%) were Black/non-Hispanic, 255 (26%) were 
Asian/Pacific Islanders, 72 (7%) were Hispanic, 54 (6%) 
were White/non-Hispanic, and one (0.1%) was an Amer- 
ican Indian/Alaskan native. 
Of the persons diagnosed with malaria, 958 (97%) 
reported recent travel outside the United States. The 
majority of individuals (n = 569; 59%) reported travel to 
Africa; 239 (24%) individuals reported travel to the Indian 
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Figure 2. Month of diagnosis of malaria in New York City, 1991-l 996. 
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Figure 3. Frequency of malaria in New York City, 1991-l 996, accord- 
ing to age and sex. 
subcontinent or the Middle East; 1 I6 (12%) reported 
travel to the Caribbean or Latin America; 34 (3%) indi- 
viduals reported travel to East or Southeast Asia; and 4 
individuals (< 1%) reported travel to Europe. Travel infor- 
mation was unavailable for 24 individuals. Six persons 
(< 1%) denied any recent travel history: one was a case of 
congenital malaria, one a case of transfusion-associated 
malaria, one case was associated with a kidney transplant 
procedure (the donor a relative from Africa), and three 
were previously reported as cases of locally acquired 
malaria.ll 
Most cases of malaria involved parasitemia with a 
single plasmodium species. Plasmodium falcaparum was 
identified as a single species in 498 (50%) of cases, R 
vivax in 350 (35%) cases, I? malariae in 54 (5%) cases, 
and R ovale in 12 (1%) cases. The species was not deter- 
mined for 65 (7%) cases. Additionally, nine cases repre- 
sented mixed infections with more than one plasmodia 
species: one (0.1%) case had P falciparum/l malariae 
infection; one (0.1%) had R ovaZe/Z? vivax; two cases 
(0.2%) were infected with l? ovaleD? malariae, and five 
cases (0.5%) had E! vivax/Pfalc@arum. The country of 
acquisition for cases of Pfalciparum and l? vivax is 
shown in Figure 4. 
Figure 4. Frequency of malaria in New York City, 1991-i 996, accord- 
ing to regional acquisition and species. 
Only 139 patients (14%) reported using malaria pro- 
phylaxis. Information concerning the types of medica- 
tion used for prophylaxis was incomplete, but failure to 
take prophylaxis according to Centers for Disease Con- 
trol and Prevention (CDC) guidelines was common. 
The median time between onset of symptoms and 
time of diagnosis was 4 days (range, O-314 days). Ninety 
percent of the cases were diagnosed within 14 days from 
the onset of symptoms. One hundred episodes of clini- 
cal complications were reported (Table 1); these included: 
thrombocytopenia (43; 4%), hemolysis (29; 3%) anemia 
(16; 2%) cerebral malaria (11; 1%) renal failure (6; 0.6%) 
and respiratory distress syndrome (2; 0.2%). The most 
serious complications, and all 4 cases resulting in death, 
were associated with Pfalczparum as the single infective 
agent or in combination with another plasmodium 
species (mixed infection). 
DISCUSSION 
Cases of imported malaria are diagnosed throughout the 
United StatesI and may occur in any locality from which 
residents travel to areas of the world with active malaria 
Table 1. Clinical Complications by Malaria Species in New York City, 1991-1996 
Complications* 
Hemolysis 
Cerebral malaria 
Renal failure 
Thrombocytopenia 
Anemia 
Respiratory distress syndrome 
Fatal outcome 
Species 
P. falciparum 
(n=498) 
17 (3%) 
10 (2%) 
6 (1%) 
21 (4%) 
7 (1%) 
0 
3 (6%) 
P. vivax 
(n=350) 
P. malariae 
(n =54) 
P ovale 
(n=12) 
Dual lnfecfion 
(n=9) 
Not Determined Total 
(n=65) (n=988) 
10 (3%) 
0 
1: (5%) 
7 (2%) 
1 (.3%) 
0 
2 (4%) 
0 
0 
0 
0 
0 
0 
0 
0 
0 
1 (8%) 
0 
0 
0 
l(ll%) 0 29 (3%) 
0 1 (2%) 11 (1%) 
0 0 6 (6%) 
l(ii%) 1 (2%) 43 (4%) 
i(ll%) 1 (2%) 16 (2%) 
l(ll%) 0 2 (2%) 
l(ii%) 0 4 (.4%) 
*Some patients have more than one complication. 
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transmission. However, most cases occur in states receiv- 
ing newly arrived immigrants and refugees.“,‘* Imported 
malaria is also commonly diagnosed in other industrial- 
ized countries that, like the United States, have had suc- 
cessful malaria eradication programs.15x16 As in the United 
States, cases typically occur among newly arrived immi- 
grants, individuals who travel to areas of the world with 
a high prevalence of malaria, returning military person- 
nel, and refugees. Imported malaria continues to present 
a health problem for other countries that have eradicated 
malaria more recently or have established malaria eradi- 
cation/control programs.17,18 
Cases of imported malaria are almost always spo- 
radic, but occasionally secondary transmission occurs in 
countries where malaria has been eradicated for many 
years. “Airport malaria” (malaria acquired from tropical 
mosquitoes imported aboard arriving airplanes) and sus- 
pected “baggage malaria” (mosquitoes imported via inter- 
national luggage) have also been reported.19,20 
In the United States, malaria eradication was accom- 
plished in the 1940s but the potential for re-introduc- 
tion of the parasite into native mosquitoes still exists. 
During the last 5 decades, local transmission of malaria 
has been reported from a variety of regions th.roughout 
the continental United States, including California and 
Florida,‘l New Jersey,? New York City,i2 Texas,23 and 
Michigan2* 
In New York City, more than 200 cases per year of 
malaria have been reported during the past 2 years, with 
most cases being diagnosed during the summer months 
when travel abroad is most frequent. The majority of indi- 
viduals providing travel histories reported travel to Africa 
and the Indian subcontinent or the Middle East. This 
reflects the country of origin of many New York City 
immigrants and refugees, 25 the destination of many trav- 
ellers (both US-born and foreign-born), and the high inci- 
dence of malaria transmission throughout Africa and Asia. 
The standardized reporting form used for data collection 
during the years of this study did not inquire about the 
country of origin of individual cases; however, most cases 
appeared to involve recent immigrants or first-generation 
descendants of immigrants. As of 1998, the reporting form 
has been modified to collect such information. 
The most common cause of infection diagnosed in 
NewYork City residents, as well as the cause of the most 
serious illness and all deaths from malaria during the past 
6 years was Pfalciparum. Falciparum malaria is known 
to cause the most serious illness (especially in non- 
immune individuals) and symptoms may vary from a mild 
flu-like illness to severe hemolysis and multiorgan failure 
(“blackwater fever”). Pulmonary disease has been well 
described in falciparum malaria, but is exceedingly rare 
in cases of vivax malaria. The case included here repre- 
sents the third such case reported in the literature.26 
Plasmodium falciparum is also the most resistant of 
the four malaria parasites commonly infecting man, and 
the inadequacy of chloroquine prophylaxis for infections 
due to Pfalciparum from Africa has long been known.27 
Drug resistance complicates both treatment and pro- 
phylaxis of malaria. 
Noncompliance with chemoprophylaxis and per- 
sonal protective measures against mosquito bites con- 
tribute significantly to the occurrence of imported 
malaria.28 Most individuals diagnosed with malaria during 
the past 6 years in New York City failed to use prophy- 
laxis.This may reflect both failure to use and lack of 
access to pre-travel medical services, especially by trav- 
elling US immigrants. Inadequate prophylaxis of travellers 
and delays in diagnosis or misdiagnosis of returning civil- 
ian travellers is common.29 The incubation period for E! 
falciparum, E! vivax, and &? ovale is usually 1 to 2 weeks 
and the vast majority of the patients in this study-period 
developed symptoms within the first 2 weeks after return 
from abroad. The incubation period for P malariae is 
usually 7 to 30 days; however, prolonged incubation peri- 
ods of many months have been well documented for R 
ovale and some strains of I! vivax, a reminder of the 
importance of a thorough travel history (including recent 
immigration) in patients presenting with signs and symp- 
toms compatible with malaria. Immigrants from areas of 
the world with endemic malaria, who are travelling to 
visit their countries of origin, may be less aware of the 
importance of malaria chemoprophylaxis than are other 
travellers.‘O 
Pre-travel counselhng should be encouraged for all 
individuals whose travel itinerary will include areas of 
the world where active malaria transmission occurs. Trav- 
ellers should receive malaria prophylaxis according to 
the drug-resistance patterns in that region, and treatment 
of cases of malaria should follow similar guidelines.31 In 
addition to chemoprophylaxis for malaria, travellers 
should be advised about the importance of practicing 
barrier protection against mosquito bites: window and 
door screens, bed netting, clothing that ensures maximum 
coverage of the body, use of sprays containing pyrethrum 
against flying insects, application of permethrin-contain- 
ing repellants to clothing and bed netting, and the appro- 
priate use of insect repellant containing diethyltoluamide 
(DEET) to exposed areas of skin, especially during hours 
of peak mosquito-biting activity. 
CONCLUSION 
During the past 6 years, malaria has been more frequently 
diagnosed in New York City and is increasingly common 
elsewhere in the United States. It is imperative that physi- 
cians and primary health providers consider this diag- 
nosis in febrile individuals with recent histories of travel 
to (or arrival from) countries where active malaria trans- 
mission occurs. Malaria may not present with the classic 
2- or 3-day pattern of spiking fever and chills, especially 
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in individuals with prior immunologic experience with 
the parasites (such as recent immigrants or refugees); the 
diagnosis should also be considered in individuals with 
appropriate recent travel histories for whom less precise 
symptoms such as headache and malaise are found, but 
for whom the diagnosis is not clear. The risk of malaria 
transmission and drug resistance patterns may vary sig- 
nificantly within a country. A precise travel history is 
important and should include the use of malaria pro- 
phylaxis and types of mosquito-barrier precautions prac- 
ticed by the individual. Outreach to US immigrant 
communities is needed concerning both the importance 
of pre-exposure prophylaxis and timely access to medical 
care should an illness occur in the returning traveller. 
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